SubsidieMeestersDrug solution for bone fracture nonunions
Genera Research aims to develop OSTEOGROW-C, a novel biological drug using patients' blood to treat bone fracture nonunion, promising effective regeneration and reduced complications.
Projectdetails
Introduction
Bone fracture nonunion (FNU) is one of the leading unmet orthopaedic clinical needs, resulting in billions of healthcare costs annually without any drug approved by regulatory agencies for this debilitating indication. Due to considerable shortcomings of the current best practices in treating bone FNUs, patients are facing increased risks and morbidity.
Current Treatment Landscape
The market has available only bone substitutes and enhancers with limited clinical efficiency, highlighting an essential need for more effective therapies. Genera Research is on its way to filling the gap with its globally patented OSTEOGROW-C product: a novel biological drug transforming patients’ blood into bone.
Project Overview
The proposed OSTEOforUNION project aims to develop and commercialize OSTEOGROW-C, an innovative drug for bone regeneration. OSTEOGROW-C is a novel treatment option for bone FNUs, an implant composed of:
- An active substance - recombinant human bone morphogenetic protein 6 (rhBMP6)
- Incorporated in an autologous blood coagulum (ABC)
- Tricalcium phosphate (TCP) ceramics added as a compression resistant matrix (CRM)
This combination forms a personalized implant that catalyzes bone growth at the implantation site.
Advantages of OSTEOGROW-C
It is easily prepared in the operating room from the patient's blood without the need for a painful bone harvesting procedure, as in current treatment practices. This method reduces associated complications and morbidities such as:
- Donor site pain
- Infection
- Nerve injuries
- Blood loss
- Iliac wing fracture
These benefits also lead to reduced additional healthcare costs.
Market Potential
OSTEOGROW-C targets the global FNU market, which serves 6 million patients yearly. Key overlapping markets include:
- Fracture Fixation
- Orthobiologics
- Bone Grafts
- BMP
OSTEOGROW-C's unique stance promises to revolutionize the FNU market. The initial market entry will concentrate on the markets in the EU, with 180,000 diagnosed long bone FNUs in Europe annually. Simultaneously, OSTEOGROW-C will be launched in the US, addressing more than 120,000 bone FNUs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 2.499.999 |
Tijdlijn
| Startdatum | 1-1-2025 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The Holy Grail in Bone regenerationGreenBone aims to revolutionize bone grafts with a synthetic Rattan wood-based implant that mimics natural bone, enhancing regeneration and targeting the spinal market by 2025. | EIC Accelerator | € 2.458.128 | 2022 | Details |
SmartFuse: Game-changer to create a new gold-standard for spinal fusion surgery with wirelessly technologyThe project aims to enhance spinal fusion surgery outcomes by integrating a wireless bio-electrical stimulation system into implants to accelerate bone growth and provide real-time healing feedback. | EIC Accelerator | € 2.500.000 | 2022 | Details |
A Health Technology Assessment of a breakthrough technology in the early diagnosis of Osteoporosis and other bone related diseases.The Porous solution aims to revolutionize osteoporosis diagnosis by using mobile ultrasound technology to assess cortical bone quality and fracture risk more effectively than current BMD methods. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Medical nanofiber technology to prevent cerebrospinal leakage in neurosurgeriesNurami's ArtiFix is a revolutionary bio-absorbable patch designed to prevent cerebrospinal fluid leaks post-surgery, improving patient outcomes and reducing healthcare costs. | EIC Accelerator | € 2.495.624 | 2024 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
The Holy Grail in Bone regeneration
GreenBone aims to revolutionize bone grafts with a synthetic Rattan wood-based implant that mimics natural bone, enhancing regeneration and targeting the spinal market by 2025.
SmartFuse: Game-changer to create a new gold-standard for spinal fusion surgery with wirelessly technology
The project aims to enhance spinal fusion surgery outcomes by integrating a wireless bio-electrical stimulation system into implants to accelerate bone growth and provide real-time healing feedback.
A Health Technology Assessment of a breakthrough technology in the early diagnosis of Osteoporosis and other bone related diseases.
The Porous solution aims to revolutionize osteoporosis diagnosis by using mobile ultrasound technology to assess cortical bone quality and fracture risk more effectively than current BMD methods.
Medical nanofiber technology to prevent cerebrospinal leakage in neurosurgeries
Nurami's ArtiFix is a revolutionary bio-absorbable patch designed to prevent cerebrospinal fluid leaks post-surgery, improving patient outcomes and reducing healthcare costs.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Ontwikkelen nieuw middel voor de lokale genezing van botbreukenDit project ontwikkelt een nieuwe formulering van microspheres met groeifactoren voor Demineralized Bone Material (DBM) om de effectiviteit bij moeilijk genezende botbreuken te verbeteren. | Mkb-innovati... | € 194.500 | 2015 | Details |
Self-feeding implants to improve and accelerate tissue healing using nutritional nanoparticlesThe NutriBone project aims to develop a patented self-feeding bone implant that enhances long-term viability and reduces failure rates for large bone defects through glycogen-based glucose release. | ERC Proof of... | € 150.000 | 2024 | Details |
Regenerative Stenting for Osteoporotic Vertebral Fracture RepairRESTORE aims to revolutionize osteoporotic vertebral fracture treatment by using 3D-printed biodegradable stents and thermoresponsive hydrogels for personalized bone regeneration and repair. | ERC Consolid... | € 2.039.473 | 2024 | Details |
A 3D-printable biomimetic bone regeneration materialPRIOBONE aims to validate a novel 3D-printable, bone-mimetic material for critical-size bone defects, offering a customizable, cost-effective solution to improve healing outcomes. | ERC Proof of... | € 150.000 | 2024 | Details |
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONSTRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Ontwikkelen nieuw middel voor de lokale genezing van botbreuken
Dit project ontwikkelt een nieuwe formulering van microspheres met groeifactoren voor Demineralized Bone Material (DBM) om de effectiviteit bij moeilijk genezende botbreuken te verbeteren.
Self-feeding implants to improve and accelerate tissue healing using nutritional nanoparticles
The NutriBone project aims to develop a patented self-feeding bone implant that enhances long-term viability and reduces failure rates for large bone defects through glycogen-based glucose release.
Regenerative Stenting for Osteoporotic Vertebral Fracture Repair
RESTORE aims to revolutionize osteoporotic vertebral fracture treatment by using 3D-printed biodegradable stents and thermoresponsive hydrogels for personalized bone regeneration and repair.
A 3D-printable biomimetic bone regeneration material
PRIOBONE aims to validate a novel 3D-printable, bone-mimetic material for critical-size bone defects, offering a customizable, cost-effective solution to improve healing outcomes.
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONS
TRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes.